Moderna (MRNA): Q1 2026 Earnings Preview – Revenue Doubling and Pipeline Progress in Focus
Key Takeaways
- Analysts expect Q1 2026 revenue of around $224 million, a significant increase from $108 million in Q1 2025.
- Consensus EPS forecast points to a loss of approximately $2.29 per share, potentially improved from prior quarters.
- Investors will watch updates on mRNA pipeline progress, including respiratory vaccines and oncology programs.
- Company reiterated 2026 revenue growth target of up to 10% over 2025's $1.9 billion.
- Historical earnings beats have led to mixed stock reactions, with volatility around guidance.
Earnings Context and Why It Matters
Moderna (MRNA)'s Q1 2026 earnings, due out on May 1 before the market opens, mark a key moment in the company's shift from COVID-19 reliance to a broader mRNA platform. After full-year 2025 revenue of $1.9 billion—down from pandemic highs—Moderna beat Q4 estimates with $678 million in sales and EPS of -$2.11. From what I see, this report serves as an important checkpoint for cost controls, international expansion, and pipeline milestones in flu, RSV, and cancer therapies. Strong execution could point to sustainable growth amid biotech competition, shaping sentiment ahead of respiratory vaccine launches.
Earnings Expectations
Wall Street looks for Q1 revenue of $223.5 million, more than doubling year-over-year from Q1 2025's $108 million, fueled by seasonal vaccine demand and grants. The EPS consensus is a loss of $2.29 per share, narrower than recent quarters thanks to reduced operating expenses.
Focus areas include net product sales from Spikevax, R&D spending, and cash position. The company has a history of EPS beats, such as the $0.51 surprise in Q4 2025, though revenue surprises have been smaller. Updates on 2026 full-year revenue guidance—up to 10% growth—and pipeline readouts will be essential. I also checked MRNA using Tickeron’s AI Screener to compare it against industry peers. Stock reactions to past reports highlight volatility, with gains on beats but sensitivity to forward guidance.
Market Reaction and Investor Sentiment
Heading into earnings, sentiment around MRNA feels cautiously optimistic, lifted by Q4 beats and 2026 growth guidance, yet checked by biotech sector headwinds and vaccine demand uncertainty. Options pricing points to a potential 9% stock move post-report, in line with historical patterns. Risks center on softer sales or approval delays, while narrower losses and positive pipeline news could drive upside. One thing that stands out to me is how guidance often sways the reaction more than the numbers themselves.
A Tool I Use for Analysis: Tickeron’s AI Screener
In my research, I often turn to Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs. It lets me filter thousands of assets using technical patterns, fundamentals, trends, volatility, and AI signals—customized by industry, market cap, indicators, and more. This helps spot trade ideas, trending names, breakouts, and opportunities far faster than manual scans, which is how I evaluated MRNA's positioning. I find it enhances my workflow for earnings previews like this one.
Forward Outlook and Key Factors to Monitor
After earnings, eyes will turn to Moderna's reiterated 2026 guidance: up to 10% revenue growth over 2025, with contributions from U.S. and international respiratory vaccines like next-gen COVID/flu combos. Cost-saving efforts, including GAAP operating expense reductions, are crucial for improving margins.
Pipeline catalysts remain prominent, such as potential approvals for mRNA-1010 flu vaccine in late 2026/early 2027 and oncology updates like mRNA-4157 personalized cancer therapy. I’m watching R&D progress, cash burn—with a solid runway—and demand for the Spikevax 2025-2026 formula. For trends, Tickeron’s AI Trend Prediction Engine offers useful insights into MRNA's momentum.
Broader factors include competition from Pfizer/BioNTech and regulatory paths for rare diseases. In my view, balanced progress here could set Moderna on track for cash breakeven by 2028.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
MRNA in +14.52% Uptrend, advancing for three consecutive days on October 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MRNA advanced for three days, in 212 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 17, 2026. You may want to consider a long position or call options on MRNA as a result. In 67 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 99 of 130 cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 55 cases where MRNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for MRNA turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 34 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
MRNA broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 1 (best 1 - 100 worst), indicating outstanding price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.655) is normal, around the industry mean (26.780). P/E Ratio (26.455) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (25.907) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of transformative medicines for patients
Industry Biotechnology
Advertisement